clinical stage life sciences venture capital investor

ReShape Lifesciences Presents New Data on Obesity Technologies

Weight Loss Data Presented At Annual Obesity Week 2017 Conference ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced new data that was presented this week at the ObesityWeek 2017 conference in Washington D.C. “Obesity has become a global epidemic that involves significant health issues, comorbidities, andContinue Reading

EnteroMedics Announces Name Change to ReShape Lifesciences Inc. (NASDAQ: RSLS)

EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that the Company has formally changed its name to ReShape Lifesciences Inc. (NASDAQ: RSLS). The new name, effective today, reflects the Company’s expansion and growth into a full-scale provider of medical devices to address the continuum of care for obesityContinue Reading

EnteroMedics Announces Acquisition Of ReShape Medical

Acquisition Adds Approved, Revenue-Generating Balloon Technology for Obesity EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that it has acquired ReShape Medical, Inc., a privately-held medical technology company that develops, manufactures and markets the ReShape Dual Weight Loss Balloon®, an FDA-approved, minimally invasive intragastric balloonContinue Reading

Health Fidelity Launches a Comprehensive Risk Adjustment Compliance Solutio

HF360 Compliance Helps Healthcare Organizations Achieve Optimal Risk Adjustment Compliance by Leveraging Advanced Technology Health Fidelity, a company that develops innovative technologies for the value-based care era, today announced the launch of HF360 Compliance, a comprehensive solution for ensuring accurate risk adjustment results and reducing audit risks. The solution leverages Health Fidelity’s natural language processingContinue Reading

EnteroMedics Begins Post-Approval Study for the Treatment of Obesity with vBloc Therapy

Study Designed to Further Demonstrate Long-Term Safety and Efficacy of vBloc for Weight Loss in Obese Patients EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the start of its U.S. FDA post-approval study of the vBloc® System, a medical device used toContinue Reading

Study Concludes Vagal Nerve Blocking with EnteroMedics’ vBloc Therapy is Cost-Effective

vBloc Therapy Cost-Effectiveness Analysis Published in the American Journal of Managed Care EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that a cost-effectiveness study analyzing vBloc Therapy for the treatment of obesity was published in the American Journal of Managed Care on August 25, 2017. TheContinue Reading

Health Fidelity Launches Comprehensive Data Acquisition Platform

HF360 Data Acquisition Optimizes Risk Adjustment Performance by Cost-Effectively Providing High Quality, Timely and Complete Patient Data Health Fidelity, a company that develops innovative technologies for the value-based care era, today announced the launch of HF360 Data Acquisition, a revolutionary platform for acquiring and aggregating patient data. HF360 Data Acquisition is a flexible platform thatContinue Reading

EnteroMedics Announces the Acquisition of the Gastric Vest System

–  At 12 Months, Gastric Vest System™ Patients Demonstrated Excess Weight Loss (EWL) of 85% and Waist Circumference Reduction of 38 Centimeters – –  Company to Host Conference Call Today at 10:00 AM Eastern Time  EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices treating obesity, metabolic diseases and other gastrointestinal disorders, announced today that itContinue Reading

Amaranth Medical Provides Clinical and Commercial Update on 115-micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold

–  Late-breaker and Symposium at EuroPCR will Review Results 9-Months Post Implantation –  Partnerships and other funding sources under consideration to support 2018 launch Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds for the interventional cardiology market, presented nine-month follow-up results from the company’s RENASCENT-II study of the APTITUDE® sirolimus-eluting bioresorbable scaffold (BRS)Continue Reading

EnteroMedics’ vBloc® Neurometabolic Therapy Recognized at 2017 Edison Awards

EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced it has been named a 2017 Bronze Edison Award Winner by the internationally renowned Edison Awards™ in the Health and Wellness category for its vBloc® Neurometabolic Therapy for the treatment of obesity. TheContinue Reading